The Depression Treatment That Does Not Require a Pill
Major depressive disorder affects approximately 280 million people globally and is the leading cause of disability in terms of years lived with disability among working-age adults in developed economies. The pharmacological treatment of depression with antidepressant medications, whose selective serotonin reuptake inhibitor class has been the first-line treatment since the late 1980s, achieves full remission in approximately one-third of patients treated with a single antidepressant trial, with successive medication trials achieving remission in additional patients but leaving approximately thirty percent of patients with treatment-resistant depression whose inadequate response to multiple adequate antidepressant trials defines the clinical population whose unmet need has driven the development of non-pharmacological alternatives including electroconvulsive therapy, ketamine and esketamine infusion, and transcranial magnetic stimulation. Transcranial magnetic stimulation applies brief magnetic pulses to the scalp overlying the left dorsolateral prefrontal cortex, the brain region whose reduced activity in depressed patients is the neural correlate that repetitive TMS stimulates to increase cortical excitability and normalise the prefrontal-limbic circuit dysregulation that underlies the depressed mood, anhedonia, cognitive slowing, and vegetative symptoms that characterise major depression. The non-invasive, outpatient, and medication-free nature of TMS, which requires no anaesthesia, creates no seizure, and produces no systemic side effects beyond the local scalp discomfort and mild headache that the repetitive magnetic pulses create, creates the treatment tolerability profile that distinguishes TMS from electroconvulsive therapy and from the systemic antidepressant side effects that medication-intolerant patients seek to avoid.
The transcranial magnetic stimulation market, valued at approximately $2.1 billion in 2026 and growing at over twelve percent annually toward $4.5 billion by 2033, reflects the expansion of TMS adoption from the academic medical centre and specialist psychiatry practice setting where the technology's early deployment was concentrated into the community psychiatry, primary care, and TMS specialty clinic settings whose growth is creating the volume that commercial TMS practice economics require. The FDA clearance of the NeuroStar system in 2008 for treatment-resistant depression established the regulatory framework that subsequent TMS system approvals, accelerated TMS protocols, and indication expansions including obsessive-compulsive disorder, anxious depression, and smoking cessation have built on, creating the cleared indication portfolio that commercial TMS practice is increasingly using to treat the full spectrum of conditions for which TMS provides documented clinical benefit.
NeuroStar and the Accelerated Protocol
Neuronetics, the US company whose NeuroStar Advanced Therapy TMS system is the most commercially deployed TMS platform in the United States with over five million TMS treatments delivered, has built its commercial market through the physician network development and practice economics optimisation that TMS adoption in the community psychiatry setting requires. The conventional TMS treatment protocol, in which patients attend thirty-six thirty-minute treatment sessions over six weeks, creates the time commitment that the treatment population's depression-related functional impairment makes adherence challenging and that the practice's scheduling logistics must accommodate across the full patient census. The Stanford Accelerated Intelligent Neuromodulation Therapy protocol, which delivers a full TMS treatment course in five consecutive days through ten daily sessions of intermittent theta-burst stimulation rather than the conventional thirty-six-session course, represents the protocol innovation that has attracted significant clinical attention for its compression of treatment time and its published remission rate data, and whose commercial implementation NeuroStar and other TMS system manufacturers are integrating into their clinical use profiles and practice support programmes.
BrainsWay, the Israeli TMS company whose Deep TMS technology uses H-coil geometry that creates a deeper and broader magnetic field than the standard figure-eight coil that NeuroStar and most conventional TMS systems use, has received FDA clearance for depression, OCD, anxious depression, and smoking cessation, with the smoking cessation and OCD indications representing the indication expansion beyond treatment-resistant depression that differentiates BrainsWay's commercial positioning from the conventional TMS market. Its Deep TMS system's ability to reach the deeper brain structures relevant to OCD, specifically the anterior cingulate cortex and medial prefrontal cortex, creates the clinical differentiation in the OCD indication where the deeper coil penetration is mechanistically relevant rather than simply different from the conventional TMS coil approach. MagVenture, the Danish TMS company with its MagPro system and the coolB65 A/P butterfly coil that reduces scalp discomfort through active cooling, competes in the TMS system market with a product portfolio whose advanced coil engineering addresses the patient experience limitations that standard TMS treatment creates.
The Miniaturisation Trend and Home TMS
The commercial development of smaller, less expensive TMS devices whose form factor allows deployment outside the dedicated TMS treatment room that conventional hospital-grade TMS systems require is the market evolution that is expanding TMS's accessible patient population beyond the patients who can attend thirty-six sessions at a specialised clinic toward the patients whose geography, functional impairment, or scheduling constraints prevent regular clinic attendance. Magstim's Horizon and the research-grade portable TMS devices whose coil and pulse generator miniaturisation creates the desktop or briefcase-sized TMS system that community health settings, home health programmes, and developing world healthcare infrastructure can accommodate at costs below the hospital-grade systems that academic medical centres deploy, represent the commercial category whose development is being watched by both TMS manufacturers and psychiatric healthcare systems as the potential pathway to substantially broader TMS access.
Top 10 Companies in Transcranial Magnetic Stimulation Technology Globally
- Neuronetics (NeuroStar): US TMS company with the most commercially deployed TMS system in the United States and over five million treatments delivered; its physician network development and its SAINT protocol integration create the commercial TMS market leader whose installed base and practice economics support define the community psychiatry TMS deployment standard.
- BrainsWay (Deep TMS): Israeli TMS company with H-coil Deep TMS cleared for depression, OCD, anxious depression, and smoking cessation; its deeper brain field penetration and its four FDA-cleared indications create the TMS company whose indication breadth differentiates its commercial positioning from conventional figure-eight coil TMS systems.
- MagVenture: Danish TMS company with MagPro systems and active-cooling coolB65 coil for improved patient comfort; its European manufacturing and its coil engineering differentiation create the international TMS system supplier whose patient experience innovation addresses the scalp discomfort that limits some patients' TMS treatment adherence.
- Magstim: UK TMS company with Horizon system for clinical and research TMS applications; its established research TMS platform and its clinical system portfolio create the TMS company whose academic and research deployment history precedes commercial clinical TMS and whose clinical product development translates research advances into clinical practice applications.
- eNeura: US neuromodulation company with SpringTMS portable TMS for migraine prevention; its at-home TMS device cleared for migraine represents the miniaturised TMS commercial product for the neurological application whose home use clearance demonstrates the regulatory pathway for portable TMS in indications beyond the clinic-administered depression protocol.
- Nexstim: Finnish TMS company with Navigated Brain Stimulation for depression and stroke rehabilitation; its MRI-guided navigated TMS that targets specific anatomical locations with individualised precision creates the image-guided TMS commercial position for the precision medicine applications whose individual neuroanatomy variation makes standardised coil placement less optimal.
- Cloud TMS: US TMS services company with managed TMS treatment programmes for psychiatric practices; its TMS-as-a-service model that provides TMS equipment, billing, and clinical support to psychiatric practices without capital equipment purchase creates the commercial deployment model that lowers the practice adoption barrier for community psychiatry TMS implementation.
- Deymed Diagnostic: Czech TMS company with TMS research and clinical systems for European and international markets; its European manufacturing and its research system portfolio create the Central European TMS company whose academic and clinical research market position serves the European neuroscience and psychiatry research community.
- Greenbrook TMS: Canadian TMS network operator with dedicated TMS treatment centres across North America; its multi-site TMS clinic operation model and its regional market development create the TMS network operator whose commercial scale across dedicated treatment centres addresses the market access problem that individual psychiatric practices face in establishing TMS programme volume.
- Ybrain: South Korean neurostimulation company with transcranial direct current stimulation and TMS development for depression; its wearable neurostimulation approach and its Korean domestic market development create the Asian neuromodulation company whose miniaturised device approach targets the home-use and primary care deployment context that conventional hospital-grade TMS systems cannot serve.